Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rituxan For Lupus Misses Primary, Secondary Endpoints

This article was originally published in The Pink Sheet Daily

Executive Summary

Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.

You may also be interested in...



Market Snapshot: After Benlysta Breakthrough, How High The Sky In Lupus?

Human Genome Sciences' Phase III breakthrough with the biologic Benlysta in lupus has renewed hope in new drugs for a difficult-to-treat disease. The question now, though, is how big can the market grow for this elusive condition, given the high unmet need

Market Snapshot: After Benlysta Breakthrough, How High The Sky In Lupus?

Human Genome Sciences' Phase III breakthrough with the biologic Benlysta in lupus has renewed hope in new drugs for a difficult-to-treat disease. The question now, though, is how big can the market grow for this elusive condition, given the high unmet need

Genentech Takes Over GlycArt Anti-CD20 Antibody Work

Enhanced antibody may work better than standard of care in blood cancers.

Related Content

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel